Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

N.D. James; A. Caty; M. Borre; B.A. Zonnenberg; P. Beuzeboc; T. Morris; D. Phung; N.A. Dawson

doi:10.1016/j.eururo.2008.11.002

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

Translated title of the contribution: Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

N.D. James, A. Caty, M. Borre, B.A. Zonnenberg, P. Beuzeboc, T. Morris, D. Phung, N.A. Dawson

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
Original language	Undefined/Unknown
Pages (from-to)	1112-1123
Number of pages	11
Journal	European Urology
Volume	55
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2008.11.002
Publication status	Published - 2009

Access to Document

10.1016/j.eururo.2008.11.002

Cite this

James, N. D., Caty, A., Borre, M., Zonnenberg, B. A., Beuzeboc, P., Morris, T., Phung, D., & Dawson, N. A. (2009). Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. European Urology, 55(5), 1112-1123. https://doi.org/10.1016/j.eururo.2008.11.002

@article{9199456f1f144f07b358599e0d81b0cd,

title = "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.",

author = "N.D. James and A. Caty and M. Borre and B.A. Zonnenberg and P. Beuzeboc and T. Morris and D. Phung and N.A. Dawson",

year = "2009",

doi = "10.1016/j.eururo.2008.11.002",

language = "Undefined/Unknown",

volume = "55",

pages = "1112--1123",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "5",

}

James, ND, Caty, A, Borre, M, Zonnenberg, BA, Beuzeboc, P, Morris, T, Phung, D & Dawson, NA 2009, 'Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.', European Urology, vol. 55, no. 5, pp. 1112-1123. https://doi.org/10.1016/j.eururo.2008.11.002

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. / James, N.D.; Caty, A.; Borre, M. et al.
In: European Urology, Vol. 55, No. 5, 2009, p. 1112-1123.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

AU - James, N.D.

AU - Caty, A.

AU - Borre, M.

AU - Zonnenberg, B.A.

AU - Beuzeboc, P.

AU - Morris, T.

AU - Phung, D.

AU - Dawson, N.A.

PY - 2009

Y1 - 2009

U2 - 10.1016/j.eururo.2008.11.002

DO - 10.1016/j.eururo.2008.11.002

M3 - Article

SN - 0302-2838

VL - 55

SP - 1112

EP - 1123

JO - European Urology

JF - European Urology

IS - 5

ER -

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. European Urology. 2009;55(5):1112-1123. doi: 10.1016/j.eururo.2008.11.002